A federal jury in California on Thursday found that Boiron Inc. did not make false representations about Oscillococcinum even though the plaintiff had alleged it was nothing but a sugar pill.
“The vast majority of patients would tell their doctors it did help them,” said Christina Sarchio, chairwoman of the commercial class action team and a partner in the Washington office of Orrick, Herrington & Sutcliffe, who represented Boiron. “We had a lot of scientific evidence to support it.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
